Myriad Genetics, Inc. announced in a press release that a study published in JCO Precision Oncology indicates their RiskScore® tool enhances breast cancer screening by aligning clinician ...
SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results